Henri Termeer has put in much of his specialized life constructing Cambridge- foundation Genzyme into a worldwide biotech source of power, and it might all enter in to an abrupt conclusion if French drug colossal Sanofi-Aventis do well in its attempts to obtain the company.

Up till now the people near to the Genzyme CEO express Xconomy that Termeer has abundant of fragmentary business and isn’t just about all set to depart.

After joining Genzyme in 1983, Termeer as president, and turned out to be the chief executive in 1985, is accredited with most important company’s development from a Boston established base into a multibillion-dollar worldwide group with approximately 12,000 employees.

However over the precedent year and a half, his authentic evidence at the group has been stained by the viral contagion discovered at its Allston Landing plant in the month of June and the consequential scarcity of its rehabilitation for genetic ailments. A mounting choir of evaluator, counting the influential objector investor Carl Icahn, has termed Termeer’s guidance into uncertainty.

However, Termeer, has depicted few indications that he’s all set to gear it relinquish. Termeer, who is the group’s chairperson, and the rest of Genzyme’s panel previous month discarded Sanofi’s unwanted tender to obtain the company for $18.5 billion.